Madrid

• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended
  2023-508163-74-00 5 2023-06-12 Major Depressive Disorder
• A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hype … Ended
  2022-503022-13-00 5 2023-06-08 Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
• Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy … Ended
  2023-503557-35-00 2 2023-06-08 thromboembolism
• A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended
  2022-501104-10-00 10 2023-06-06 Netherton syndrome (NS)
• Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Ended
  2024-512649-18-00 5 2023-06-05 Thyroid Eye Disease
• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 4 2023-06-02 Metastatic Colorectal Cancer (mCRC)
• Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended
  2022-500694-14-00 7 2023-06-02 Head and Neck Squamous Cell Cancer
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501753-36-00 5 2023-06-02 Hidradenitis Suppurativa
• Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended
  2023-505237-27-00 2 2023-06-02 Healthy volunteers
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT … Ended
  2023-510446-24-00 4 2023-05-30 Cancer cachexia
• Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coron … Ended
  2023-504639-42-00 4 2023-05-26 SARS-CoV-2 infection
• A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) Ended
  2023-508422-95-00 9 2023-05-25 Cancer
• Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Ended
  2024-511292-15-00 4 2023-05-25 Advance Radioactive-Iodine Refractory Differentiated Thyroid Cancer
• Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed … Ended
  2023-509471-17-00 4 2023-05-24 Metastatic or unresectable locally advanced BRAF V600E/K mutation posi
• Study of M5049 in DM and PM Participants (NEPTUNIA) Ended
  2022-501351-82-00 4 2023-05-23 Dermatomyositis, Polymyositis
• A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi … Ended
  2022-501601-12-00 4 2023-05-22 Diffuse large B-cell Lymphoma
• A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line met … Ended
  2023-506385-30-00 9 2023-05-22 Advanced Urothelial Carcinoma
• A Phase 1, Multicentre, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single IV Dose of Rezafungin Acetat … Ended
  2022-501985-23-00 3 2023-05-18 Fungal infections
• A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74) Ended
  2023-509747-27-00 4 2023-05-18 Heart failure
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn … Ended
  2023-508777-91-00 10 2023-05-16 Moderately to Severely Active Crohn's Disease

Showing 2,977–3,000 of 3,550 trials